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Early-onset schizophrenia-spectrum (EOSS) disorders
(onset of psychotic symptoms before 18 years of age) rep-
resent a severe variant associated with signiﬁcant chronic
functional impairment and poor response to antipsychotic
treatment. All drugs with proven antipsychotic effects
block dopamine D2 receptors to some degree. The ongoing
development of the dopamine and other neurotransmitter
receptor systems during childhood and adolescence may af-
fect clinical response and susceptibility to side effects in
youth. A literature search was conducted of clinical trials
of antipsychotics in children and adolescents with EOSS
disorders between 1980 and 2007 from the Medline data-
base, reference lists, and conference proceedings. Trials
were limited to double-blind studies of duration of 4 or
more weeks that included 15 or more patients. Ten clinical
trials were identified. Antipsychotic medications were con-
sistently found to reduce the severity of psychotic symp-
toms in children and adolescents when compared with
placebo. The superiority of clozapine has been now demon-
strated relative to haloperidol, standard-dose olanzapine,
and ‘‘high-dose’’ olanzapine for EOSS disorders. How-
ever, limited comparative data are available regarding
whether there are differences among the remaining second-
generation antipsychotics (SGAs) in clinical effectiveness.
The available data from short-term studies suggest that
youth might be more sensitive than adults to developing an-
tipsychotic-related adverse side effects (eg, extrapyramidal
side effects, sedation, prolactin elevation, weight gain). In
addition, preliminary data suggest that SGA use can lead
to the development of diabetes in some youth, a disease
which itself carries with it significant morbidity and mor-
tality. Such a substantial risk points to the urgent need to
develop therapeutic strategies to prevent and/or mitigate
weight gain and diabetes early in the course of treatment
in this population.
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Introduction
Many clinicians view schizophrenia in childhood or ad-
olescence as relatively rare; however, this belief is not
fully accurate. Although the prevalence of childhood-
onset schizophrenia (onset of psychotic symptoms before
13 years of age) is indeed very low (approximately 1/100
cases of schizophrenia),
1 the incidence of schizophrenia
risessharplyatabout12–14yearsofage.
2Before18years
of age, approximately 12%–33% of individuals with
schizophrenia would develop the onset of their illness
3,4
and thus would be classified as having an early-onset
schizophrenia-spectrum (EOSS) disorder.
When Diagnosticand StatisticalManualofMental Dis-
orders, Third/Fourth Edition (DSM-III/IV), criteria are
rigorously applied, clinical and neurobiological studies
have demonstrated a number of phenomenological sim-
ilarities in the presentation of schizophrenia-spectrum
disorders (ie, schizophrenia, schizoaffective disorder,
schizophreniform disorder) in children/adolescents and
adults with regard to the relative frequency of core psy-
chotic symptoms (eg, auditory hallucinations, delusions,
thought disorder), neurocognitive impairments, psycho-
physiological abnormalities, and the presence of struc-
tural brain abnormalities.
5,6 In comparison to adults
with schizophrenia, there is an increased rate of premor-
bid abnormalities
7 and a rarity of well-formulated delu-
sions reported by children/adolescents.
8 EOSS disorder
patients frequently manifest early impairments in expres-
sive language, motor function, and transient symptoms
of pervasive developmental disorder well in advance of
the first onset of psychotic symptoms.
7 However, children
1Towhomcorrespondenceshouldbeaddressed;DivisionofChild
and Adolescent Psychiatry, University of Minnesota Medical
School, 2450 Riverside Avenue, F256/2B, Minneapolis, MN
55454; tel: 612-273-9775, fax: 612-273-9779, e-mail:
kumra002@umn.edu.
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60with EOSS disorder and autistic disorder can be distin-
guished on the basis of developmental history, clinical
features, family history, and age at onset.
9 Higher rates
of psychiatric comorbidity in EOSS disorder (ie, atten-
tion-deficit hyperactivity disorder, oppositional defiant
disorder, and major depressive disorder) appear to be an-
other importantdevelopmentaldifference betweenadults
and youth with schizophrenia.
10 However, in children/
adolescents pharmacological treatment of these comor-
bid conditions is rare that may reflect a lack of empiri-
cally driven guidelines for appropriate treatment and/
or the hierarchical diagnostic system that is characteristic
of DSM-IV.
10 It is important to note that psychotic
symptoms are not specific to schizophrenia, and the dif-
ferential diagnosis of EOSS disorder would include sub-
stance abuse, mood and anxiety disorders, and various
medical conditions (eg, seizure disorders, infectious dis-
ease, metabolic and endocrine disorders, central nervous
system lesions, etc). Also, there are a sizable number of
children and adolescents with subsyndromal conditions
who report psychotic symptoms that would not meet
the severity/duration criteria required by DSM-IV to
qualify for a diagnosis of schizophrenia.
11
NaturalisticdatashowthatEOSSdisorderisachronic,
disabling disease, which, in the majority of cases, requires
long-term antipsychotic medication treatment.
3,12–16
Studies of antipsychotic medications in adults with
chronic schizophrenia may provide guidance for the
treatment of children and adolescents with schizophre-
nia, but the treatment of pediatric patients has unique de-
velopmental aspects. To date, all the drugs with proven
antipsychotic effects block dopamine D2 receptors to
some degree. Although the pathophysiology of schizo-
phrenia remains unclear, it has been hypothesized that
increased dopaminergic neurotransmission in the meso-
limbic pathways produces the positive symptoms of
the disease.
17,18 Based on this working hypothesis, it is
thoughtthatantipsychoticmedicationsworkbyblocking
dopamine D2 receptors, thus dampening psychotic symp-
toms.
19 Preclinical studies suggest that there are substan-
tial changes occurring within the dopamine system and
otherneurotransmittersystemsduringmidtolateadoles-
cence in the prefrontal cortex (PFC) in normative devel-
opment
20 that may have implications for understanding
the mechanism of onset of schizophrenia that typically
occurs during late adolescence and early adulthood.
21
Thespecificmaturationalchangesinthedopaminerecep-
tor system include decreases in dopamine cell density
22;
peaking of basal dopamine levels,
23 dopamine turn-
over,
24 and dopaminergic PFC input
25; and changes in
D1 and D2 receptor concentrations in the striatum.
26,27
Overall, these data suggest that, relative to adulthood,
adolescence is characterized by increases in basal PFC
dopamine levels. These maturational changes in the do-
pamine receptor system (as well as other neurotransmit-
ter systems) during childhood and adolescence could
potentially have implications for clinical response as
well as an increased susceptibility to side effects (eg, ex-
trapyramidal side effects [EPS], prolactin elevation,
sedation, weight gain) observed in youth exposed to an-
tipsychotic drugs.
Aside from making the initial diagnosis, choice of an-
tipsychotic is probably the most important decision that
a child and adolescent psychiatrist makes in collaborat-
ing with the patient/family in treating a young patient
with a schizophrenia-spectrum disorder. Over the past
few years, second-generation antipsychotics (SGAs)
have been preferred over first-generation antipsychotics
(FGAs) in the treatment of EOSS disorder.
28 However,
increasing concerns about the adverse side effects associ-
ated with SGA treatment in children and adolescents
point to the need to reexamine the risk/benefit of these
agents. This descriptive review aims to systematically ex-
amine the evidence from randomized, double-blind com-
parison studies supporting the use of antipsychotics in
EOSS disorder. The implications of recent treatment re-
search are discussed including the identification of high
priority areas for future research in this population.
Methods
Asystematicliterature searchusingtheMedline database
was performed to identify all random assignment, con-
trolled pediatric clinical trials of antipsychotics in chil-
dren and adolescents with schizophrenia-spectrum
disorders whose results were published in the peer-
reviewed literature from 1970 to 2007. Because we
wereaware ofseveraltreatmentstudiesthat were recently
completed, we queried investigators and contacted man-
ufacturers to locate additional studies and included data
obtained from conference proceedings. Trials limited to
double-blind studies of duration of 4 or more weeks with
15 or more patients were included in this review.
Results
We identified 10 double-blind studies that met our crite-
ria for final review. These studies and their findings are
presented below and summarized in table 1 by drug class
(FGA, 3 studies; SGA, 7 studies).
First-Generation Antipsychotics
There have been 3 major studies that have examined the
efficacyofFGAs inthe treatmentof EOSSdisorder. Two
of these utilized placebo controls and found a modest but
significant superiority of active medication for acute pos-
itive symptoms over placebo: a crossover trial of moder-
ate dose haloperidol (average daily dose 95 CPZ
equivalents) in 16 children
29 and a 3-arm, parallel group
study comparing loxitane (average daily dose 875 CPZ
equivalents), haloperidol (average daily dose 490 CPZ
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61Table 1. Characteristics of Studies Included in the Review
Authors
Drugs, Mean Daily
Dose (SD) Duration Participants Effectiveness Adverse Effects Limitations
Pool et al
30 Loxapine, 87.5 mg;
haloperidol, 9.8 mg;
placebo
4 weeks N = 75, mean age:
;15.5 years
Both treatments
signiﬁcantly reduced
BPRS total ratings
compared with placebo.
No signiﬁcant differences
observed between active
treatment groups.
EPS (eg, muscle rigidity)
noted in 19 (73%) of 26
receiving loxapine and
18 (72%) of 25 subjects
receiving haloperidol.
Sedation also
problematic.
Short duration of
treatment; small
sample size
Realmuto et al
31 Thiothixene, 16.2 mg;
thioridazine, 178 mg
6 weeks N = 21, mean age:
;15.5 years
Both treatments
signiﬁcantly reduced
BPRS total scores.
Clinical improvement
noted within the ﬁrst
7 days of treatment.
Marked sensitivity to
sedative effects of
medication, dose
reductions required for
both medications
Short duration of
treatment, small
sample size
Spencer et al
29 Crossover design:
haloperidol, 1.8 mg,
vs placebo
6 weeks N = 16, mean age
(SD): ;8.9 years
CGI-I much/very much
improved: 12 (75%) of
16; marked reduction
in severity of persecutory
ideation and
hallucinations
Sedation observed at
optimal doses
Short duration of
treatment, small
sample size
Kumra et al
69 Clozapine, 176 mg
(149); haloperidol,
16 mg (8)
6 weeks N = 21, mean age
(SD): 14.0 6 2.3
years
Clozapine > haloperidol
in terms of positive
(SAPS total) and negative
symptoms (SANS total)
One third of
clozapine-treated
patients discontinued
treatment prematurely
due to neutropenia or
seizures
Short duration
of treatment
Sikich et al
64 Risperidone, 4 mg (1.2);
olanzapine, 12.3 mg
(3.5); haloperidol,
5.0 mg (2)
8 weeks N = 50, mean age
(SD): 14.7 6 2.7
years; broad
range of children
with psychotic
disorders included
All treatments signiﬁcantly
reduced BPRS-C total
scores from baseline
to end point; CGI-I
much/very much
improved
and  20% BPRS-C
reduction: 74%
risperidone,
88% olanzapine, 54%
haloperidol
Prevalence of
extrapyramidal
symptoms
and weight gain higher
and more severe in youth
compared with published
data from adult studies
Short duration of
treatment, differences
in the diagnosis
across the treatment
groups, concomitant
use of antidepressants
and/or mood stabilizers
Shaw et al
68 Clozapine, 327 mg
(113); olanzapine,
18.1 mg (4.3)
8 weeks N = 25, mean
age: ;12 years
Clozapine > olanzapine
with respect to
improvement in negative
symptoms (SANS)
Marked weight gain
at 4 kg during the
8-week trial noted in
both groups, at 2-year
follow-up, 6 (40%) of
15 patients were observed
to have dyslipidemia
Short duration of
treatment, study
powered to detect
only large treatment
effects
6
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.Table 1. Continued
Authors
Drugs, Mean Daily
Dose (SD) Duration Participants Effectiveness Adverse Effects Limitations
Kumra et al
70 Clozapine, 403.1 mg
(201.8); olanzapine,
26.2 mg (6.5)
12 weeks N = 39, mean age
(SD): 15.6 (2.1)
Clozapine > ‘‘high-dose’’
olanzapine with respect
to improvement in
negative symptoms
(SANS) for 12 weeks,
CGI much/very much
improved and 30%
BPRS reduction: 66%
clozapine, 33%
olanzapine
Five (13%) of 39 patients
(3 clozapine, 2
olanzapine)
gained >7% of their
baseline body weight;
high incidence of
dyslipidemia
and prediabetes seen
with both drugs
Short duration of
treatment, small
sample size
Robb et al,
58
Findling et al
57
Aripiprazole, 10 mg;
aripiprazole, 30 mg;
PBO
6 weeks N = 302, mean age:
15.5 years (range,
13–17)
Aripiprazole (10-mg
and 30-mg doses) >
PBO in terms of
improvement from
baseline to end
point on the PANSS
Total Score compared
with placebo (26.7
and 28.6, respectively;
placebo, -21.2; Last
Observation Carried
Forward (LOCF)
Mild to moderate
severity of spontaneously
reported Adverse Events
(AEs): extrapyramidal
disorder, somnolence,
akathisia; mean change
in weight from baseline
was minimal (10 mg, no
change; 30 mg, 0.2 kg)
No data available from
drug-naive subjects to
assess whether
aripiprazole is truly
‘‘weight neutral’’; high
placebo response rate
Haas et al
52 Risperidone, 1–3 mg;
risperidone, 4–6 mg;
PBO
6 weeks N = 160, mean
age (SD): 15.6
years (1.3)
Both risperidone groups >
PBO on the PANSS
Total Score (risperidone
1- mg: 19.9 and
risperidone 4–6 mg:
20.7, respectively;
placebo, 7.8; LOCF)
Higher dose risperidone
group had a greater
incidence of EPS,
dizziness, and hypertonia
compared with lower
dose group
Short duration of
treatment
Kryzhanovskaya
et al
50
Olanzapine, 11.1 mg
(4.0); PBO
6 weeks N = 107, mean age
(SD): 16.2 years
(1.3)
Olanzapine > PBO in
terms of improvement
from baseline to end
point on the BPRS-C
(P = .003) and CGI-S
(P = .004), respectively.
Treatment response rate
was not significantly
different between
olanzapine (37.5%) and
PBO (25.7%).
Mean olanzapine-induced
weight gain (4.3 6 3.3 kg)
higher and more severe in
youth compared with
adult studies
Short duration of
treatment, high placebo
response rate
Note: EPS, Extrapyramidal side effects; BPRS, Brief Psychiatric Rating Scale; CGI-I, Clinical Global Impression—Improvement Scale; CGI-S, Clinical Global
Impression—Severity of Illness; BRPS-C, Brief Psychiatric Rating Scale for Children; SAPS, Scale for the Assessment of Positive Symptoms, SANS, Scale for the Assessment
of Negative Symptoms; PBO, placebo; PANSS, Positive and Negative Syndrome Scale.
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sequivalents), and placebo in 75 adolescents.
30 The third
studydirectlycomparedahigh-potencyFGAthiothixene
(average daily dose 324 CPZ equivalents, n = 13) with
a lower potency FGA thioridazine (average daily dose
178 CPZ equivalents, n = 7) in adolescents.
31 All these
studiesfoundsignificantextrapyramidal symptomsaffect-
ing 70% of those treated with haloperidol or loxitane and
50% of those treated with thiothixene. In addition, all
studies reported significant—often intolerable—sedation.
The side effect profile of the FGAs, particularly motor
side effects and the development of tardive dyskinesia,
has led to their decreased utilization among child and ad-
olescent psychiatrists.
32 In general, side effects associated
with FGAsoccur along acontinuum: agentswithlow do-
pamine D2 binding affinity/potency typically produce
marked sedation, orthostasis, and moderate weight
gain and medications with high dopamine D2 binding af-
finity/potency more frequently cause motor side effects
that seem partially dose related. There have been no
long-term studies demonstrating the safety of FGAs in
children, and thus, data must be extrapolated from adult
studies. Casereportsof antipsychotic-related tardivedys-
kinesia (TD) have been reported in adults and children
for all the available antipsychotics, including the
SGAs.
33 In adults, TD is of particular concern, with
an incidence of approximately 5% per year of FGA ex-
posure and a spontaneous remission rate of 2.5%.
33 In
2 large adult studies, the incidence of TD over 5 years
was 20%–25%.
34–36 In addition, adult data suggest that
FGAs appear to have minimal benefit for neurocognitive
symptomsincomparisontoSGAs.
37However,itremains
unclear to what extent the improvements in cognition
demonstrated for SGAs in adult studies reflect normali-
zation of cognitive deficits, practice effects, lack of inclu-
sion of a healthy control group in some studies, or
reduced burden of EPS.
Second-Generation Antipsychotics
The current published practice parameter for the assess-
ment and treatment of children and adolescents with
schizophrenia
38 does not address the question of which
antipsychotic to prescribe as a first-line agent for patients
based on phase of illness, severity of clinical symptoms,
and side effectrisk. Concerns aboutthe safety and lack of
efficacy of the FGAs prompted a search for more effec-
tive agents with better tolerability. As a class, SGAs have
affinity for both dopamine D2 receptors as well as for
serotonin5-hydroxytryptamine(5-HT)2andincludecloza-
pine, risperidone (and its active metabolite paliperidone),
olanzapine,quetiapine,andziprasidone.
39Inaddition,ari-
piprazole, another novel antipsychotic that is a partial do-
pamine agonist, is often classified as an SGA. The SGAs
have become the standard treatment for EOSS disorder.
38
As a class, these agents have a reduced propensity to
cause adverse motor side effects and prolactin elevations
when compared with FGAs of similar potency. However,
as with FGA agents, each of the SGAs tends to be more
prone to certain adverse effects that exist along a spec-
trum.
40 These side effects appear directly related to the
unique receptor-binding profiles of each of the SGAs.
For example, some SGAs (eg, quetiapine, clozapine) rap-
idly dissociate from the dopamine D2 receptor
41 possibly
allowing normal surges in dopamine to overcome recep-
tor blockade in the nigrostriatal and tuberoinfundibular
pathways.In contrast,aripiprazole actsasaselective par-
tial agonist at the dopamine D2 receptor.
42 These unique
featuresmayresult inthelower EPSliability andminimal
effects on prolactin levels of clozapine, quetiapine, and
aripiprazole compared with other SGAs such as risperi-
done in children.
43–47 Whether the improved tolerability
ofthe SGAswill enhancetreatmentadherenceinchildren
and adolescents with EOSS disorder remains an impor-
tant, but unanswered question.
Nonadherence to treatment is a widespread phenome-
non among youth with schizophrenia, due to such factors
as impaired cognition, lack of insight, and side effects as-
sociated with antipsychotic treatment. Also, the quality
of relationships with clinicians during acute admission
appears to be an important determinant of patients’
and families’ attitudes toward treatment. Enhancing
suchrelationshipsmayyieldimportantclinicalbenefits.
48
To date, there has been little systematic research exam-
ining the benefits of psychological interventions aimed
at promoting medication adherence in children/adoles-
cents. Although there are no data available regarding
the use of risperidone microspheres (Risperdal Consta)
in children and adolescents, injectables and long-acting
formulations of antipsychotics may also offer benefits
in terms of ensuring treatment adherence in select
patients.
Placebo-Controlled Studies
As of the writing to this article, several US pharmaceu-
tical manufacturers have short-term, placebo-controlled
studiesthatarecurrentlyunderwayand/orthathavebeen
recently completed. It is possible that the patients in-
cluded in these trials may not be ‘‘real-world’’ patients
because they and their families must be willing to partic-
ipate in a placebo-controlled trial. Also, while the care-
fully supervised conditions of a clinical trial allows
children and adolescents with schizophrenia-spectrum
disorders to be closely monitored, there remains some
ethical concerns about withholding medications in chil-
dren with EOSS disorder, particularly those who are se-
verely ill, because it could be argued that participation in
thesetrialsmayexposethemtosubstantialrisks.
49Toour
knowledge, the results from 3 short-term placebo-
controlled studies that have now confirmed the efficacy
and tolerability of SGAs (risperidone, olanzapine, aripi-
prazole) relative to placebo in EOSS disorder have been
presented at national meetings and the manuscripts for
these data are currently under review.
64
S. Kumra et al.A double-blind, flexible dose study randomized adoles-
centswithschizophreniatoolanzapine(n = 72)orplacebo
(n = 35).
50 Improvements in overall psychopathology and
illness severity were significantly greater in olanzapine-
treated subjects (P = .003, .004, respectively). However,
olanzapine-treated patients experienced somnolence,
treatment-emergent liver enzyme abnormalities, prolactin
elevation, and excessive weight gain (4.3 6 3.3 vs 0.1 6 2.8
kg, P < .001) compared with placebo. Although the pro-
file of side effects appeared to be similar in adolescents vs
adults, as seen in other studies,
44,51 the authors noted that
the magnitude of olanzapine-induced weight gain may be
greater in adolescents and was alarming in comparison to
antipsychotic medications. Overall, the extant data might
prompt clinicians to consider olanzapine as a ‘‘second-
line’’ agent for children and adolescents with schizophre-
nia-spectrum disorders.
A double-blind, placebo-controlled study randomized
patients to receive either risperidone 1–3 mg/day
(n = 55), 4–6 mg/day (n = 51), or placebo (n = 54) for
up to 6 weeks.
52 The mean change score in overall psycho-
pathology was significantly greater in patients receiving
‘‘low-’’ or ‘‘high-’’ dose ranges of risperidone (1–3 mg:
21.3 6 19.6; 4–6 mg: -21.2 6 18.3) compared with pla-
cebo (8.9 6 16.1). The most commonly reported side
effects were somnolence, agitation, and headache in the
1- to 3-mg group and extrapyramidal disorder, dizziness,
and hypertonia in the risperidone 4- to 6-mg group.
52 The
investigators reported no prolactin-related side effects or
adverse reactions related to glucose or lipid metabolism
inthis short-term study.
52 However, risperidone treatment
in children has been associated with galactorrhea, in-
creased appetite, and moderate weight gain that can
lead to metabolic problems and steatohepatitis.
51,53–56
Also, dose-dependent EPS
46,47 have been noted by other
investigators and suggest that the overall benefit-risk pro-
file of risperidone appears to be optimal in the lower dose
ranges (1–4 mg) for children/adolescents.
A double-blind, placebo-controlled study randomized
patients to aripiprazole 10 mg/day (n = 99), 30 mg/day
(n = 97), or placebo (n = 98) for up to 6 weeks.
57,58 Im-
provement in overall psychopathology was significantly
greater in the aripiprazole groups (10 mg, P = .04; 30 mg,
P = .006) vs placebo.
58 The most commonly reported
side effects were EPS, tremor, and somnolence.
57 The in-
cidence of clinically significant weight gain (>7% in-
crease) was modest in all treatment arms (placebo:
1.0%; 10 mg, 4%; 30 mg, 5.2%).
57 Although these data
suggest that aripiprazole may be ‘‘weight neutral’’ in chil-
dren and adolescents, a post hoc analysis in treatment-
naive subjects was not conducted.
Active-Comparator Controlled Studies
To our knowledge, there are very limited data from con-
trolled treatment trials that have compared the effective-
nessofSGAsvsFGAstypicallyusedasfirst-linetreatments
for children and adolescents with schizophrenia-
spectrum disorders. At present, the appropriate position-
ing of the FGAs within treatment algorithms for EOSS
disorder remains controversial, particularly in light of
recent adult data from the Clinical Antipsychotic Trials
ofAntipsychoticEffectivenessstudy(CATIE)
59andCost
Utility of the Latest Antipsychotic Drugs in Schizophre-
nia Study (CUtLASS-1)
60 involving adults with schizo-
phrenia. Also, a recent meta-analysis of the treatment
of EOSS disorder concluded that the FGAs were more
effective and caused less weight gain than SGAs. How-
ever, there were several methodological flaws in this
meta-analysis (eg, absence of control group in several
studies, cohort effects by year of study, differences
in the quality of studies, limited sample size of most stud-
ies included) that cast doubts on the validity of its
conclusions.
61
In adults, the CATIE trial was a publicly funded, di-
rect, randomized, double-blind trials of multiple SGAs
in comparison to a mid-potency FGA. Although there
appearedtobeamodesteffectivenessadvantageforolan-
zapine as compared with perphenazine, risperidone, and
quetiapine in the CATIE trial, no advantage was ob-
served for the other SGAs vs perphenazine.
59 Further,
olanzapine was associated with more adverse effects, par-
ticularly related to weight and related metabolic abnor-
malities.
59 It should be noted that the results from the
CATIE study differed significantly from some pharma-
ceutical company–sponsored short-term trials using hal-
operidol as the comparator.
62,63
In children and adolescents, the Treatment of Adoles-
cent Psychosis Study, an 8-week, double-blind study that
compared risperidone, olanzapine, and haloperidol in 50
pediatric subjects (ages 8–19 years) with psychosis (60%
of whom had EOSS disorder) found no statistical differ-
ence in the response rate or symptom reduction between
agents, althoughthere was a numeric trend favoring the 2
SGAs. Further, the time to all-cause treatment discontin-
uation was significantly longer in the olanzapine group
than either the risperidone or haloperidol group
(P < .05).However,therewassignificantweightgain(es-
pecially with the SGAs) and frequent extrapyramidal
symptoms noted across treatment conditions even with
the 2 SGAs.
64
Also in children, a federally funded, 8-week, random-
ized, flexible dose, double-blind trial—the ‘‘Treatment of
Early-Onset Schizophrenia Spectrum Disorders
(TEOSS)’’ study—compared 2 SGAs (risperidone and
olanzapine) to a weight-neutral FGA (molindone) in
youth 8–18 years of age with EOSS disorder. TEOSS en-
rolled 119 youth
65; initial publication of results from the
study is anticipated within 1 year. Interestingly, weight
gain associated with olanzapine treatment in this study
was significantly greater than weight gain associated
with either of the other 2 agents studied and led the
65
Efficacy and Tolerability of Second-Generation AntipsychoticsNational Institute of Mental Health Data and Safety
Monitoring Board to close randomizations to the
olanzapine arm prematurely.
65 Preliminary analyses of
the data revealed that there were significant reductions
in positive symptoms observed with all 3 medications;
however, adequate response was achieved in fewer
than half of youth with EOSS disorder (Dr Lin Sikich,
2007).
After risperidone becomes available in a generic for-
mulation, one important question for EOSS disorder
treatment research will be to clearly define the potential
advantages and cost-effectiveness of the other SGAs with
respect to risperidone, particularly as policy makers and
third-party payers question the incremental costs associ-
ated with these treatments. In children and adolescents
with EOSS disorder, an open-label pilot study comparing
2 SGAs with ‘‘continuously high’’ dopamine D2 receptor
occupancy (ie, olanzapine and risperidone) with quetia-
pine, which is associated with only ‘‘transiently high’’ D2
receptor occupancy,
66 found superior reduction in over-
all psychopathology for risperidone as compared with
quetiapine but quetiapine had a more favorable side ef-
fect profile.
67 These preliminary data provide evidence
for a hypothesis that there may be important differences
in treatment outcome among currently available SGAs in
EOSS disorder. However, to our knowledge, there have
been no published double-blind studies that have
compared the effectiveness of risperidone with other
SGAs that may be comparable in terms of effectiveness
but which may have the potential for significantly
fewer adverse effects (eg, quetiapine, ziprasidone,
aripiprazole).
Controlled Studies in Treatment-Refractory EOSS
Disorder
Clozapine is generally reserved as a second-line interven-
tion for pediatric patients with treatment-refractory
schizophrenia due to its potential toxicities with regard
to seizures and hematological adverse events.
68–70 In
adults, clozapine has been shown consistently to have
several advantages over FGAs in terms of overall clinical
response and reduction of positive symptoms,
71 lower
rates of EPS,
71–73 and tardive dyskinesia.
74,75 Initial
open-label studies of clozapine used to treat children
with EOSS disorder demonstrated a similar effectiveness
for both positive and negative symptoms
76–80 and aggres-
sive outbursts.
81
From a preclinical standpoint, olanzapine is more sim-
ilar to clozapine than any other SGA in terms of a signif-
icant affinity for 5-HT2a and D4 receptors in comparison
to D2 receptors and a significant affinity for 5-HT2c,5 -
HT3, 5-HT6,D 3,D 1, muscarinic (especially M1), a1,
and H1 receptors.
82,83 However, the drugs are by no
means identical from a pharmacological standpoint
and an initial pilot study in treatment-refractory youth
with EOSS disorder suggested that there may be impor-
tant differences in clinical effectiveness between the 2
compounds.
84 These preliminary findings were
confirmed in 2 head-to-head comparisons that compared
clozapine with olanzapine at both standard
68 and higher-
than-customary doses (up to 30 mg/day)
70 in children
with EOSS disorder who had primarily failed at least 2
trials of SGAs. Although olanzapine was shown to be ef-
fective for some treatment-refractory children and ado-
lescents with schizophrenia in both studies, clozapine
wasfoundtobesuperiorintermsofreductionofnegative
symptoms and less consistently in terms of severity of ill-
ness and overall clinical response.
68,70
Because of clinicians’ concern regarding clozapine’s
side effects (eg, agranulocytosis, weight gain, diabetes)
andareluctanceonthepartofpatients/familiestosubmit
to frequent blood testing, we believe that clozapine ther-
apy remains underutilized. Although clozapine is often
considered a treatment of last resort, some clinicians
will attempt to switch patients who have been stabilized
on clozapine to another drug after they have been dis-
charged from hospital. For these reasons and due to
the relative rarity of EOSS disorder, it has been difficult
to conduct systematic, long-term studies of the safety of
clozapine treatment in children/adolescents. However,
there are some long-term safety data for clozapine. In
a retrospective chart review of 172 hospitalized children
with serious emotional disturbances treated with cloza-
pine (median observation period 8 months), the cumula-
tive probability of developing a hematological adverse
event (mainly neutropenia) over a 1-year period was
16.1%, which seems somewhat higher than what typically
has been reported in adult studies.
85 However, the prob-
ability of developing agranulocytosis in this pediatric
sample was 0.99%, which is comparable to that observed
in adult studies.
85
WeightGainand MetabolicSideEffects AssociatedWith
SGA Treatment
Weight gain has emerged as one of the most significant
and problematic side effects for children and adolescents
treated with SGAs and a significant barrier to treatment
adherence. Though considered a class effect associated
withallSGAs,arecentreviewinchildrenandadolescents
indicated that the risk of weight gain is more substantial
with clozapine and olanzapine, moderate with risperi-
done and quetiapine, and low with ziprasidone and ari-
piprazole.
45 Treatment with SGAs is associated with
ageneralincreaseincaloricintake
86thatcancausearapid
increase in body weight for 50%–60% of children and
adolescents in the first few months of therapy that
may not reach a plateau even after 1 year of treatment.
45
Thesechangesclearlyexceedthe expectedweightchanges
associated with normal growth as indicated by a prospec-
tive naturalistic study that tracked body mass index
66
S. Kumra et al.percentile scores up to 1 year.
45 The medical consequen-
ces of weight gain in children and adolescents include the
metabolic syndrome and insulin resistance, which can
then lead to type 2 diabetes.
87 A 10-year naturalistic
study revealed that the Kaplan-Meier estimate for
new-onset diabetes mellitus was approximately 43% for
adults treated with clozapine.
88 Although there are no
comparable long-term data for children, there are emerg-
ing data suggesting alarming levels of metabolic adverse
effects (eg, impaired glucose tolerance, dyslipidemia) in
pediatric subjects treated long term with SGAs (up to
1 year), including antipsychotic-naive patients.
44
Atpresent,themechanismunderlyingthedevelopment
of obesity and insulin resistance in children and adoles-
cents treated with SGAs is not fully understood. There
are some animal data that appetite stimulation/weight
gain associated with SGAs (ie, clozapine, olanzapine)
is mediated by activation of hypothalamic AMP-protein
kinase that has been linked to blockade of the histamine
H1 receptor.
89 It is thought that both obesity and some
directdrugeffectonglucosemetabolismcontributetothe
problem of insulin resistance in adults with schizophre-
nia.
88 Based on this working model, it is possible that
interventions designed to limit weight gain during the ini-
tial phases of treatment, when weight gain with SGAs
such as risperidone is most likely to occur,
90 may di-
minish the likelihood of long-term adverse metabolic
consequences.
There are no good treatment guidelines regarding the
best therapeutic strategy to address treatment-emergent
obesity, diabetes, or hyperlipidemiain children or adoles-
centstreatedwithSGAs.Insomecases,childrenandado-
lescents can be managed with nonpharmacological
therapy directed at minimizing the occurrence of these
adverse events (eg, nutritional counseling). However,
when these problems are severe or fail to respond to be-
havioral interventions, clinicians frequently contemplate
a change in antipsychotic medication and/or the addition
of a weight-loss agent (possible agents that have been put
forward include metformin, orlistat, amantidine, and
sibutramine). However, this is an area in which further
research is needed. There are concerns that amantadine
and sibutramine could exacerbate psychiatric symptom-
atology and that orlistat may be poorly tolerated due to
flatulence and associated stigmatization.
Despite some initial data regarding the effectiveness of
metformin to address weight gain and obesity in children
treated with psychotropic drugs,
91 questions have been
raised regarding both the use and long-term safety of
pharmacological approaches as therapeutic/preventive
strategies for limiting antipsychotic-induced weight
gain.
92 How long do these interventions need to be con-
tinued? What are the consequences of the intervention? It
isthoughtthatlifestylemodificationearlyinthecourseof
antipsychotic treatment remains a promising avenue
for preventing weight gain and other adverse outcomes
in the majority of children receiving antipsychotic
medications.
92,93
Evidence-based behavioral interventions that have
been developed for obese nonpsychiatrically ill chil-
dren
94–96 emphasize diet modifications, increase in phys-
icalactivity,andother behavioralinterventionssimilar to
programs that have been developed for adults with
chronic and first-episode schizophrenia.
97 To our knowl-
edge, no specific programs have been specifically tailored
for use in acutely ill adolescents with schizophrenia-
spectrum disorders who, in the majority of cases, are
of normal weight prior to SGA treatment. Recent mon-
itoring recommendations for weight gain and metabolic
and endocrine side effects in youth exposed to antipsy-
chotics have been put forward by Correll and Carlson
(2006)
55; however, a more formal consensus statement
is currently being developed by the American Academy
of Child and Adolescent Psychiatry and will be published
shortly.
Future Priorities
There are several gaps in our knowledge base regarding
the treatment of EOSS disorder. In particular, most of
the studies reviewed herein have focused on short-term
reductions in symptomatic outcomes and have not mea-
sured functional outcomes. Also, there has been a dearth
of information regarding the utility of adjunctive psycho-
socialtreatmentsandthere havebeen relatively fewhead-
to-head comparisons of currently available SGAs. In
addition, there is a clear need for studies that examine
the mechanisms by which antipsychotics medication
work in pediatric populations and studies of interven-
tions designed to address important adverse events
such as antipsychotic-induced weight gain.
To date, a major obstacle to conducting informative
treatment studies in EOSS disorder has been subject re-
cruitment. There are a number of reasons for this prob-
lem that have been examined in detail elsewhere.
64 For
example, substance misuse is a frequent comorbidity in
youth with schizophrenia, and it is difficult to determine
that psychotic symptoms are not substance induced par-
ticularly when treatment needs to be initiated symptom-
atically. Thus, these patients may not be included in
clinical trials. The problem of subject recruitment has
beenovercomeinrecentindustryandfederallysponsored
trials with the use of multisite studies. In addition, we
would argue that intervention studies in this population
should consider incorporating features of both efficacy
and effectiveness trial designs. For example, although
for scientific reasons it may be preferable to exclusively
focus on patients with schizophrenia who do not require
the addition of mood-stabilizing drugs, a sizable propor-
tion of children and adolescents with schizophrenia-
spectrumdisorderspresentwhiletakingsuchmedications
and acutely tapering them prior to randomization could
67
Efficacy and Tolerability of Second-Generation Antipsychoticsdestabilize them, jeopardize their safety, and/or prevent
their retention in a clinical trial. Thus, consideration
should be given to designing protocols that include
patients who have been on stable doses of such medica-
tions for at least 30 days and permit continuing them
throughoutthestudy.Lastly,theinclusionofapsychoso-
cial treatment as a platform could enhance subject
recruitment and retention.
Summary
A substantial proportion of individuals who develop
schizophrenia will have the onset of their illness during
early adolescence. An early onset of psychosis bodes
poorly for prognosis, with an increased likelihood of
chronic, treatment-resistant symptoms and disability.
Until recently, there were few well-controlled treatment
trials that focused on the treatment of EOSS disorder.
There is an emerging consensus that aripiprazole and ris-
peridone are effective drugs for the first-line treatment of
acute exacerbation of psychosis in adolescents with
schizophrenia, and both drugs may soon have a formal
FDA indication for this population. Initial data had sug-
gested that the olanzapine and risperidone were clinically
more effective than a high-potency FGA, haloperidol, in
adolescents with psychosis.
64 However, as seen in the
CATIE trial in adults,
59 emerging data from TEOSS sug-
gest that these differences are probably not clinically sig-
nificant and that a substantial proportion of youth with
schizophrenia respond poorly to currently available first-
line antipsychotic treatments. To date, studies involving
clozapine in treatment-refractory EOSS disorder have
consistently demonstrated the superiority of clozapine
with respect to haloperidol
98 and olanzapine at standard
doses
68 and olanzapine at higher-than-customary doses
70
with respect to reduction in negative symptoms and, less
consistently, with respect to overall response.
70,98 Across
treatment studies of EOSS disorder, the emerging data
indicate that adolescents might be particularly vulnerable
tosideeffects(weightgain,metabolicproblems,elevation
in prolactin levels, sedation) suggesting limited generaliz-
ability of adult studies to younger patients.
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